治疗性抗体糖链的结构和功能作用

The structure and the effector functions of N-glycan of therapeuticmonoclonal antibodies

抗体药物具有特异、高效等特点,越来越多的抗体药物应用于肿瘤和自身免疫等疾病的治疗。抗体药物全部是Ig G类型的抗体,Ig G的Fc段具有N-糖链,糖链的结构复杂,具有微观不均一性,糖链的组成和结构影响抗体的结构、效应功能和药代动力学性质。通过宿主细胞基因编辑和优化宿主细胞培养条件等方法技术可以改变抗体糖链的结构。本文就抗体糖链对抗体功能的影响以及糖链的改造进行综述。

More and more therapeutic monoclonal antibodies （mAbs） are widely used for treating various illnesses such as cancer and autoimmune diseases due to the specific and efficient properties of mAbs. All of the currently licensed therapeutic mAbs are of the IgG class. Fc region of IgG has a N-glycan which is structural heterogeneity. The glycan on Fc region has many significant roles on the structure, the effector functions and pharmacokinetics of mAbs. The glycan of Fc region can be changed through genome editing and optimization of cell culture condition. This review presents an overview of the role of the various glycans in the effector functions of therapeutic mAbs and the impact of various parameters on glycosylation pattern of therapeutic mAbs.